<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00925756</url>
  </required_header>
  <id_info>
    <org_study_id>CCTG 590</org_study_id>
    <nct_id>NCT00925756</nct_id>
  </id_info>
  <brief_title>CCR5 Inhibitor Treatment Intensification on CD4+ T-cell Recovery</brief_title>
  <official_title>The Impact of CCR5 Inhibitor Treatment Intensification on CD4+ T-cell Recovery and Gene Expression Profiles in HIV-Infected Patients With Viral Suppression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Diego</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of California, Los Angeles</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Southern California</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>California HIV/AIDS Research Program</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Diego</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      CCTG 590 is a open-label study to evaluate the impact of therapy intensification with&#xD;
      Maraviroc (MVC) (a CCR5 inhibitor) to a stable suppressive HIV antiretroviral regimen on the&#xD;
      rate of CD4+ T-cell recovery and gene expression profiles. Patients on a stable first-line&#xD;
      HIV regimen with continued viral suppression and sub-optimal CD4+ T-cell counts will be&#xD;
      eligible for this study. Those who are found to be eligible will have MVC (dose-adjusted to&#xD;
      background HIV regimen) added to their current HIV regimen for 24 weeks. After the 24 week&#xD;
      intensification, the MVC will be discontinued, the original antiretroviral regimen will be&#xD;
      continued and the subjects will be followed for an additional 12 weeks.&#xD;
&#xD;
      The investigators hypothesize that MVC will improve the rate of CD4 recovery. This improved&#xD;
      CD4 recovery will be associated with favorable changes in gene expression profiles of genes&#xD;
      involved with CD4 maintenance and circulation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Blunted CD4+ T-cell responses during viral control may be a consequence of on-going T-cell&#xD;
      destruction in the regenerative phase of CD4 recovery from activation-induced apoptosis&#xD;
      and/or reduced production from decreased thymic output. Maraviroc, a CCR5 inhibitor, may&#xD;
      improve the clinical status of HIV-infected by two distinct mechanisms. First, by blocking&#xD;
      HIV entry into CD4+ T-cells, CCR5 inhibitors have direct antiviral activity. Second, as the&#xD;
      pro-inflammatory state of HIV infection up-regulates CCR5 ligands and receptors, this CCR5&#xD;
      receptor antagonist may abrogate immune activation and resultant T-cell apoptosis.&#xD;
      Importantly, MVC binds CCR5 receptors without inducing intracellular signaling or altering&#xD;
      cell-surface expression. Potentially, MVC intensification during viral suppression with ART&#xD;
      may further decrease persistent activation-induced apoptosis and improve repair and&#xD;
      remodeling of lymphoid tissue leading to increased CD4+ T-cell recovery and function.&#xD;
&#xD;
      The aim of this study is to evaluate a potentially therapeutic immunomodulatory effect of&#xD;
      MVC. Several measures of immune homeostasis will be determined in this study, including&#xD;
      functional genomic analysis and extended T-cell phenotyping. Genes responsive to MVC therapy&#xD;
      will be identified and categorized into functional groups. Based upon existing literature of&#xD;
      the identified genes and observed immune responses (change in CD4/CD8 subsets) during MVC&#xD;
      therapy, a model of CCR5 responsive-genes and potential impact on immune recovery will be&#xD;
      outlined. Potentially, individuals experiencing immune discordance during suppressive ART may&#xD;
      be better treated by MVC antiretroviral intensification.&#xD;
&#xD;
      1. We hypothesize that expression will decrease among genes involved in immune activation&#xD;
      (NF-kB, MAPK, nuclear factor of activated T-cells, MYD88 and STAT1), apoptosis (Fas ligand&#xD;
      and TRAIL) and trafficking/repopulation of T-cells (CCR5, MIP-1α, MIP-1β and RANTES) and&#xD;
      increase among genes involved in tissue repair (platelet-derived growth factor, insulin-like&#xD;
      growth proteins and osteoblast-specific transcription factor).&#xD;
&#xD;
        1. The gene expression profiles induced by MVC will be associated with a favorable increase&#xD;
           in the rate of CD4+ T-cell recovery.&#xD;
&#xD;
        2. The rate of CD4 recovery (cells/month) will be greater during MVC compared to before.&#xD;
&#xD;
        3. The proportion of cells expressing activation/ apoptosis markers will decrease from&#xD;
           baseline and this decrease will be associated with improved CD4 recovery.&#xD;
&#xD;
        4. The proportion of naïve cells will increase from baseline and this increase will be&#xD;
           associated with improved CD4 recovery.&#xD;
&#xD;
        5. The rate of CD4 recovery will be greater among those subjects receiving PI-containing&#xD;
           treatment regimens compared to those receiving NNRTI-containing treatment regimen.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 20, 2008</start_date>
  <completion_date type="Actual">April 11, 2014</completion_date>
  <primary_completion_date type="Actual">May 2, 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Differences in Gene Expression Profiles Obtained at Baseline and Week 4 and Week 24.</measure>
    <time_frame>Baseline to Week 24</time_frame>
    <description>To determine differential gene expression in T-Cells due to MVC exposure between week 0, 4 and 24 weeks.&#xD;
Repeated measures (RM) ANOVA was used to identify genes whose expression changed over the course of MVC administration. Multivariate permutation tests under default settings (80% confident no more than 10% false positives) were performed using BRB-Array Tools. Gene assignment to temporal profiles was performed using a non- parametric clustering algorithm in Short Time-series Expression Miner (STEM)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>CD4+ T-cell Absolute Count and Percentage at Baseline, Weeks 4 and 24.</measure>
    <time_frame>Baseline to Week 24</time_frame>
    <description>To compare the CD4+/CD8+ T-cell absolute count and percentage change at Weeks 4 and 24 from Baseline. Wilcoxon signed rank test was used to assess changes in T cell counts, percentages, CD4+ T cell recovery slopes and changes in T cell phenotypes measured by flow cytometry.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in CD4+/CD8+ T-cell Immune Activation, Maturation, Regulatory and Apoptosis Markers at Baseline and Weeks 4 and 24.</measure>
    <time_frame>Baseline to Week 24</time_frame>
    <description>To compare the percent change of CD4+/CD8+ T-cell</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>Maraviroc 150 mg, 300 mg, or 600 mg twice daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This was a single arm study where Maraviroc was added for 24 weeks.&#xD;
Maraviroc was dose-adjusted for concomitantly administered HIV medications according to the manufacture's recommendations:&#xD;
150 mg twice daily with strong CYP3A4 inhibitors, including:&#xD;
Protease inhibitors (except tipranavir/ ritonavir)&#xD;
Delavirdine&#xD;
ketoconazole, itraconazole, clarithromycin, nefazadone, telithromycin&#xD;
Darunavir/r + etravirine&#xD;
300 mg twice daily with non-inducers/ non-inhibitors of CYP3A4, including:&#xD;
Tipranavir/ ritonavir&#xD;
Nevirapine&#xD;
All NRTIs&#xD;
Enfuvirtide&#xD;
600 mg twice daily with strong CYP3A4 inducers, including:&#xD;
Efavirenz, etravirine&#xD;
rifampin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Maraviroc</intervention_name>
    <description>Maraviroc will be given dose-adjusted to background HIV treatment (150 mg, 300 mg, or 600 mg twice daily)</description>
    <arm_group_label>Maraviroc 150 mg, 300 mg, or 600 mg twice daily</arm_group_label>
    <other_name>Selzentry</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. HIV-1 infection&#xD;
&#xD;
          2. All available CD4+ T cell counts within the last 12 months of screening below 350&#xD;
             cells/mm3 (minimum of 3 values obtained &gt; 30 days apart).&#xD;
&#xD;
          3. HIV treatment with a stable (for at least 6 months) antiretroviral regimen consisting&#xD;
             of at least 2 NRTIs and either a protease inhibitor boosted with low dose ritonavir or&#xD;
             an NNRTI. A stable regimen is defined as no additions or deletions for more than 14&#xD;
             cumulative days.&#xD;
&#xD;
          4. Patient considered to be receiving initial HIV regimen (history of medication&#xD;
             substitution for toxicity is allowed).&#xD;
&#xD;
          5. All available plasma HIV RNA levels within the last 12 months are below the level of&#xD;
             detection. Isolated values that are detectable but &lt; 1000 copies will be allowed as&#xD;
             long as the plasma HIV RNA levels before and after this detectable time point are&#xD;
             undetectable - The subject should have a minimum of 3 values obtained &gt; 30 days apart.&#xD;
&#xD;
          6. Females of childbearing potential must have a negative serum pregnancy test at&#xD;
             screening and agree to use a double-barrier method of contraception throughout the&#xD;
             study period.&#xD;
&#xD;
          7. Men and women age ≥ 18 years.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Current antiretroviral regimen contains tenofovir disoproxil fumarate AND didanosine&#xD;
             in combination.&#xD;
&#xD;
          2. History of chronic hepatitis C (defined as HCV antibody positive and HCV RNA&#xD;
             detectable).&#xD;
&#xD;
          3. History of chronic active hepatitis B (defined as surface antibody negative, surface&#xD;
             antigen positive and HBV DNA detectable).&#xD;
&#xD;
          4. Concurrent use of G-CSF or GM-CSF.&#xD;
&#xD;
          5. Prior or concurrent use of IL-2.&#xD;
&#xD;
          6. Prior or concurrent use of a CCR5 inhibitor.&#xD;
&#xD;
          7. Active drug or alcohol use or dependence that, in the opinion of the investigator,&#xD;
             would interfere with adherence to study requirements.&#xD;
&#xD;
          8. Use of any immunomodulator, HIV vaccine, or investigational therapy within 30 days of&#xD;
             study entry.&#xD;
&#xD;
          9. Use of human growth hormone within 30 days prior to study entry.&#xD;
&#xD;
         10. Initiation of testosterone or anabolic steroids within 30 days prior to study entry.&#xD;
             (Exception: Chronic replacement dosages in patient's with diagnosed hypogonadism is&#xD;
             allowed).&#xD;
&#xD;
         11. Evidence of splenic sequestration or suppressed bone marrow function:&#xD;
&#xD;
               -  Clinical or radiographic evidence of significant splenomegaly.&#xD;
&#xD;
               -  History of leukemia or lymphoma.&#xD;
&#xD;
               -  History of myelosuppressive chemotherapy or irradiation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sheldon Morris, MD</last_name>
    <role>Study Chair</role>
    <affiliation>UC San Diego AntiViral Research Center (AVRC)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Richard Haubrich, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Diego</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Southern California</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University California San Diego</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Harbor-UCLA</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>June 18, 2009</study_first_submitted>
  <study_first_submitted_qc>June 19, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 22, 2009</study_first_posted>
  <results_first_submitted>May 13, 2020</results_first_submitted>
  <results_first_submitted_qc>August 6, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">August 19, 2020</results_first_posted>
  <last_update_submitted>August 6, 2020</last_update_submitted>
  <last_update_submitted_qc>August 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, San Diego</investigator_affiliation>
    <investigator_full_name>Sheldon Morris</investigator_full_name>
    <investigator_title>Clinical Professor</investigator_title>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>low CD4 recovery</keyword>
  <keyword>Low CD4 recovery despite HIV control</keyword>
  <keyword>Treatment experienced</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Maraviroc</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 13, 2008</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/56/NCT00925756/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Maraviroc Intensification</title>
          <description>Maraviroc will be added to patient's existing HIV treatment regimen dose-adjusted to background HIV medications&#xD;
Maraviroc: Maraviroc will be given dose-adjusted to background HIV treatment</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Maraviroc Intensification</title>
          <description>Maraviroc will be added to patient's existing HIV treatment regimen dose-adjusted to background HIV medications&#xD;
Maraviroc: Maraviroc will be given dose-adjusted to background HIV treatment</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="32"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48.9" spread="9.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>White, not Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Differences in Gene Expression Profiles Obtained at Baseline and Week 4 and Week 24.</title>
        <description>To determine differential gene expression in T-Cells due to MVC exposure between week 0, 4 and 24 weeks.&#xD;
Repeated measures (RM) ANOVA was used to identify genes whose expression changed over the course of MVC administration. Multivariate permutation tests under default settings (80% confident no more than 10% false positives) were performed using BRB-Array Tools. Gene assignment to temporal profiles was performed using a non- parametric clustering algorithm in Short Time-series Expression Miner (STEM)</description>
        <time_frame>Baseline to Week 24</time_frame>
        <population>32 participants received intervention and were followed for CD4+ counts. 25 of 32 participants had microarray analysis done.</population>
        <group_list>
          <group group_id="O1">
            <title>Maraviroc Intensification</title>
            <description>Maraviroc will be added to patient's existing HIV treatment regimen dose-adjusted to background HIV medications&#xD;
Maraviroc: Maraviroc will be given dose-adjusted to background HIV treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Differences in Gene Expression Profiles Obtained at Baseline and Week 4 and Week 24.</title>
          <description>To determine differential gene expression in T-Cells due to MVC exposure between week 0, 4 and 24 weeks.&#xD;
Repeated measures (RM) ANOVA was used to identify genes whose expression changed over the course of MVC administration. Multivariate permutation tests under default settings (80% confident no more than 10% false positives) were performed using BRB-Array Tools. Gene assignment to temporal profiles was performed using a non- parametric clustering algorithm in Short Time-series Expression Miner (STEM)</description>
          <population>32 participants received intervention and were followed for CD4+ counts. 25 of 32 participants had microarray analysis done.</population>
          <units>-fold TNF downregulation</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CD4+ T-cell Absolute Count and Percentage at Baseline, Weeks 4 and 24.</title>
        <description>To compare the CD4+/CD8+ T-cell absolute count and percentage change at Weeks 4 and 24 from Baseline. Wilcoxon signed rank test was used to assess changes in T cell counts, percentages, CD4+ T cell recovery slopes and changes in T cell phenotypes measured by flow cytometry.</description>
        <time_frame>Baseline to Week 24</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Maraviroc Intensification</title>
            <description>Maraviroc will be added to patient's existing HIV treatment regimen dose-adjusted to background HIV medications&#xD;
Maraviroc: Maraviroc will be given dose-adjusted to background HIV treatment</description>
          </group>
        </group_list>
        <measure>
          <title>CD4+ T-cell Absolute Count and Percentage at Baseline, Weeks 4 and 24.</title>
          <description>To compare the CD4+/CD8+ T-cell absolute count and percentage change at Weeks 4 and 24 from Baseline. Wilcoxon signed rank test was used to assess changes in T cell counts, percentages, CD4+ T cell recovery slopes and changes in T cell phenotypes measured by flow cytometry.</description>
          <units>cells/mm^3</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Wk 4 CD4+ cells (absolute)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.50" lower_limit="-21.5" upper_limit="32.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk 4 CD8+ cells (absolute)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46" lower_limit="-41.5" upper_limit="96.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk 24 CD4+ cells (absolute)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.75" lower_limit="16.75" upper_limit="64.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk 24 CD8+ cells (absolute)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.00" lower_limit="3.25" upper_limit="178.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in CD4+/CD8+ T-cell Immune Activation, Maturation, Regulatory and Apoptosis Markers at Baseline and Weeks 4 and 24.</title>
        <description>To compare the percent change of CD4+/CD8+ T-cell</description>
        <time_frame>Baseline to Week 24</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Maraviroc Intensification</title>
            <description>Maraviroc will be added to patient's existing HIV treatment regimen dose-adjusted to background HIV medications&#xD;
Maraviroc: Maraviroc will be given dose-adjusted to background HIV treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Change in CD4+/CD8+ T-cell Immune Activation, Maturation, Regulatory and Apoptosis Markers at Baseline and Weeks 4 and 24.</title>
          <description>To compare the percent change of CD4+/CD8+ T-cell</description>
          <units>cells/mm^3</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Wk 4 CD4+ total</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.62" lower_limit="-0.61" upper_limit="1.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk 4 CD4+ naive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.47" lower_limit="-1.64" upper_limit="0.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk 4 CD4+ central memory</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.43" lower_limit="-1.56" upper_limit="4.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk 4 CD4+ effector memory</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.33" lower_limit="-1.81" upper_limit="1.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk 4 CD4+ effector</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" lower_limit="-0.10" upper_limit="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk 4 CD4+ immune senescence</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.12" lower_limit="-1.16" upper_limit="0.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk 24 CD4+ total</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.12" lower_limit="-0.55" upper_limit="2.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk 24 CD4+ naive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.52" lower_limit="-0.98" upper_limit="2.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk 24 CD4+ central memory</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.15" lower_limit="-2.98" upper_limit="2.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk 24 CD4+ effector memory</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.30" lower_limit="-2.04" upper_limit="0.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk 24 CD4+ effector</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" lower_limit="-0.15" upper_limit="0.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk 24 CD4+ immune senescence</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.25" lower_limit="-0.78" upper_limit="0.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk 4 CD8+ total</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.90" lower_limit="-0.92" upper_limit="2.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk 4 CD8+ naive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.45" lower_limit="-2.32" upper_limit="0.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk 4 CD8+ central memory</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.83" lower_limit="-0.16" upper_limit="2.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk 4 CD8+ effector memory</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.73" lower_limit="-0.64" upper_limit="3.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk 4 CD8+ effector</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.90" lower_limit="-3.58" upper_limit="1.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk 4 CD8+ immune senescence</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.83" lower_limit="-4.05" upper_limit="1.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk 24 CD8+ total</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.38" lower_limit="-1.01" upper_limit="4.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk 24 CD8+ naive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.15" lower_limit="-2.15" upper_limit="0.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk 24 CD8+ central memory</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.75" lower_limit="-0.45" upper_limit="1.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk 24 CD8+ effector memory</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.80" lower_limit="-0.89" upper_limit="2.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk 24 CD8+ effector</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.68" lower_limit="-7.06" upper_limit="1.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk 24 CD8+ immune senescence</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.30" lower_limit="-8.29" upper_limit="0.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Maraviroc Intensification</title>
          <description>Maraviroc will be added to patient's existing HIV treatment regimen dose-adjusted to background HIV medications&#xD;
Maraviroc: Maraviroc will be given dose-adjusted to background HIV treatment</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Altered mental status</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Sheldon Morris</name_or_title>
      <organization>UCSD</organization>
      <phone>6195438080</phone>
      <email>shmorris@ucsd.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

